Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients

NCT01189903 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

OTHER

Sponsor class

Conditions

Asian Colorectal Cancer Patients

Interventions

DRUG: Regorafenib

Sponsor

National University Hospital, Singapore